Mouse models with global or CF-specific (Tcf21 promoter-driven) TREK-1 deletion had greatly reduced cardiac fibrosis following TAC, although there was no apparent effect on CF-to-MF differentiation [234]. Here, KCNK2 is linked to cystic fibrosis.